Quinupristin/dalfopristin: A therapeutic review

Clinical Therapeutics

Volumn 23, Issue 1, 2001, Pages 24-44

  Allington, Douglas R ^a   Rivey, Michael P ^a  

^a UNIVERSITY OF MONTANA   (United States)

Author keywords

Enterococcus faecium; Quinupfistin dalfopristin; Streptogramin; Therapeutic review

Indexed keywords

CYCLOSPORIN; DALFOPRISTIN; QUINUPRISTIN;

ANTIBACTERIAL ACTIVITY; BACTERIAL INFECTION; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HEADACHE; HUMAN; NAUSEA; PAIN; PRURITUS; RASH; REVIEW; VOMITING;

EID: 0035153910     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(01)80028-X     Document Type: Article

References (47)

1. Quinupristin/dalfopristin, a new addition to the antimicrobial arsenal
2. A novel antimicrobial agent joins the battle against resistant bacteria
3. Clinical implications of nosocomial gram-positive bacteremia and superimposed antimicrobial resistance
4. Impact of changing pathogens and antimicrobial susceptibility patterns in the treatment of serious infections in hospitalized patients
5. An overview of nosocomial infections, including the role of the microbiology laboratory
6. Methicillin-resistant Staphylococcus aureus: Long-term care concerns
7. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in North America
8. Cost of treating infections caused by methicillin-resistant staphylococci and vancomycin-resistant enterococci
9. Gram-positive resistance: Challenge for the development of new antibiotics
10. Streptogramins: An answer to antibiotic resistance in grampositive bacteria
11. Current and future management of infections due to methicillinresistant staphylococci infections: The role of quinupristin/dalfopristin
12. Optimal treatment of complicated skin and skin structure infections
13. Activity of quinupristin/dalfopristin against gram-positive bacteria: Clinical applications and therapeutic potential
14. Pharmacodynamic analysis of the activity of quinupristin-dalfopristin against vancomycinresistant Enterococcus faecium with differing MBCs via time-kill-curve and postantibiotic effect methods
15. Influence of erythromycin resistance, inoculum growth phase, and incubation time on assessment of the bactericidal activity of RP 59500 (quinupristin-dalfopristin) against vancomycin-resistant Enterococcus faecium
16. Quinupristin/dalfopristin: A novel selective-spectrum antibiotic for the treatment of multi-resistant and other gram-positive pathogens
17. Occurrence and epidemiology of resistance to virginiamycin and streptogramins
18. The pharmacokinetics of quinupristin/dalfopristin in laboratory animals and in humans
19. Quinupristin/dalfopristin
20. Focus on quinupristin/dalfopristin: An investigational streptogramin antibiotic for the treatment of multidrug-resistant gram-positive infections
21. Pharmacokinetics of quinupristin-dalfopristin in continuous ambulatory peritoneal dialysis patients
22. Bactericidal and inhibitory activity of quinupristin/dalfopristin against vancomycin- and gentamicin-resistant Enterococcus faecium
23. In-vitro bactericidal activity of quinupristin/dalfopristin alone and in combination against resistant strains of Enterococcus species and Staphylococcus aureus
24. In-vitro activity and killing effect of quinupristin/dalfopristin (RP59500) on nosocomial Staphylococcus aureus and interactions with rifampicin and ciprofloxacin against methicillinresistant isolates
25. In-vitro activity of quinupristin/dalfopristin compared with other widely used antibiotics against strains isolated from patients with endocarditis
26. Evaluation of in vitro activity of quinupristin/dalfopristin and comparator antimicrobial agents against worldwide clinical trial and other laboratory isolates
27. In-vitro and in-vivo antibacterial activity of quinupristin/dalfopristin
28. Comparative in-vitro activities of moxifloxacin, trovafloxacin, quinupristin/dalfopristin and linezolid against staphylococci
29. A review of in-vitro antibacterial activity of quinupristin/dalfopristin against methicillin-susceptible and -resistant Staphylococcus aureus
30. Prevalence of resistance to MLS antibiotics in 20 European university hospitals participating in the European SENTRY surveillance programme
31. In vitro activity of LY333328, an investigational glycopeptide antibiotic, against enterococci and staphylococci
32. Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin and nonquinolones linezolid, quinupristindalfopristin, gentamicin, and vancomycin against clinical isolates of ciprofloxacinresistant and -susceptible Staphylococcus aureus strains
33. Comparative in-vitro activity of quinupristin/dalfopristin against Enterococcus spp
34. Quinupristin/dalfopristin: Therapeutic potential for vancomycinresistant enterococcal infections
35. Antipneumococcal activities of a ketolide (HMR 3647), a streptogramin (quinupristin-dalfopristin), a macrolide (erythromycin) and a lincosamide (clindamycin)
36. Activity of quinupristin/dalfopristin and its components against Haemophilus influenzae
37. Synergic activity of vancomycin-quinupristin/dalfopristin combination against Enterococcus faecium
38. Postantibiotic effect and postantibiotic sub-MIC effect of quinupristin-dalfopristin against gram-positive and-negative organisms
39. Prospective, randomized dose-ranging open phase II pilot study of quinupristin/dalfopristin versus vancomycin in the treatment of catheter-related staphylococcal bacteremia
40. The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium
41. Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: Two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin, or vancomycin
42. Treatment of gram-positive nosocomial pneumonia. Prospective randomized comparison of quinupristin/dalfopristin versus vancomycin
43. Effect of quinupristin/dalfopristin on the outcome of vancomycinresistant Enterococcus faecium bacteraemia: Comparison with a control cohort
44. Safety and tolerability of quinupristin/dalfopristin: Administration guidelines
45. Stability of quinupristin/dalfopristin (RP59500) solutions and compatibility studies for use in clinical conditions